BROOKE PRUITT: Open Payments
NPI 1093021826 · JONESBORO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,341 in 86 payments from 14 companies in 2025. Trend: 2023 $1,413 · 2024 $1,364 · 2025 $1,341
Food & beverage: $1,341
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 18 | $270 |
| AstraZeneca Pharmaceuticals LP | 10 | $199 |
| Novartis Pharmaceuticals Corporation | 20 | $181 |
| Abbott Laboratories | 9 | $181 |
| Novo Nordisk Inc | 8 | $156 |
| Alnylam Pharmaceuticals Inc. | 6 | $99 |
| Boston Scientific Corporation | 1 | $58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $45 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 5 | $43 |
| BridgeBio Pharma, Inc. | 2 | $33 |
Products named: WAINUA, LEQVIO, VYNDAQEL, AVEIR, Wegovy, AMVUTTRA, ELIQUIS, CDS - MCT/CEM Monitoring.
Industry payments across AR — which companies pay providers there.
